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Abstract
Background: Circumventricular organs (CVO) are cerebral areas with incomplete endothelial blood-brain barrier
(BBB) and therefore regarded as “gates to the brain”. During inflammation, they may exert an active role in
determining immune cell recruitment into the brain.
Methods: In a longitudinal study we investigated in vivo alterations of CVO during neuroinflammation, applying
Gadofluorine M- (Gf) enhanced magnetic resonance imaging (MRI) in experimental autoimmune encephalomyelitis,
an animal model of multiple sclerosis. SJL/J mice were monitored by Gadopentate dimeglumine- (Gd-DTPA) and
Gf-enhanced MRI after adoptive transfer of proteolipid-protein-specific T cells. Mean Gf intensity ratios were
calculated individually for different CVO and correlated to the clinical disease course. Subsequently, the tissue
distribution of fluorescence-labeled Gf as well as the extent of cellular inflammation was assessed in corresponding
histological slices.
Results: We could show that the Gf signal intensity of the choroid plexus, the subfornicular organ and the area
postrema increased significantly during experimental autoimmune encephalomyelitis, correlating with (1) disease
severity and (2) the delay of disease onset after immunization. For the choroid plexus, the extent of Gf
enhancement served as a diagnostic criterion to distinguish between diseased and healthy control mice with a
sensitivity of 89% and a specificity of 80%. Furthermore, Gf improved the detection of lesions, being particularly
sensitive to optic neuritis. In correlated histological slices, Gf initially accumulated in the extracellular matrix
surrounding inflammatory foci and was subsequently incorporated by macrophages/microglia.
Conclusion: Gf-enhanced MRI provides a novel highly sensitive technique to study cerebral BBB alterations. We
demonstrate for the first time in vivo the involvement of CVO during the development of neuroinflammation.
Background
The central nervous system (CNS) may no longer be con-
sidered immune privileged but rather a site of selective
immune activity [1,2]. This so-called restricted immunity
is warranted by the barrier function of capillary endothe-
lium, which channels the entry of serum proteins and
immune cells from the blood to the CNS or the cere-
brospinal fluid (CSF), respectively [1]. Although the
blood-brain barrier (BBB) covers most parts of the CNS,
certain brain regions including the choroid plexus as well
as structures that line the cavity of the third and of the
fourth ventricle are devoid of a tight BBB and are in per-
manent contact to blood-born molecules and cells. These
“exposed” areas, called circumventricular organs (CVO),
are characterized by a dense capillary network with wide
perivascular areas. Assumably, specialized ependymal
cells, the tanycytes, act as a flexible barrier controlling
the exchange of substances between CVO and the sur-
rounding brain parenchyma as well as the CSF [3,4].
Besides neuroendocrine functions, CVO provide an
access route for immune cells into the brain and might
therefore guide CNS immune surveillance. The capacity
of the choroid plexus to build a bridge for immune cells
trafficking from the blood circulation into the CSF and
the subarachnoid space was demonstrated in physiologi-
cal [5] as well as under inflammatory conditions [6].
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during experimental autoimmune encephalomyelitis
(EAE), an animal model of multiple sclerosis (MS), indi-
cating, that these unprotected CNS areas play a key role
for pathological immune processes of the brain [7]. How-
ever, until recently no reliable method had been available
to survey CVO in vivo. Assuming a crucial function as
“gates to the brain” for immune cells, the visualization of
alterations in CVO might become of diagnostic and ther-
apeutic value for the assessment of neuroinflammatory
conditions, similar to the detection of BBB impairment
by gadopentetate dimeglumine- (Gd-DTPA) enhanced
MRI, the current gold standard for the evaluation of dis-
ease activity in MS. New developments in high field
strength MRI and novel contrast media provide opti-
mized means to detect lesions and localize alterations in
BBB integrity, even in small rodent disease models such
as murine EAE [8]. The novel gadolinium-based contrast
agent Gadofluorine M (Gf) was recently shown to facili-
tate the visualization of CNS lesions and cranial nerve
inflammation [8-10]. Gf was originally applied for the
detection of malignant lymph nodes [11], atherosclerotic
plaques [12], or peripheral nerve damage [13].
In this study, we demonstrated for the first time that
Gf-enhanced MRI represents a unique tool to in vivo
visualize alterations of CVO. The magnitude of Gf accu-
mulation in the choroid plexus and other CVO increased
during active inflammation, correlated with disease activ-
ity, and could be used to differentiate between EAE ani-
mals and controls. Furthermore, Gf facilitated the
detection of otherwise occult inflammatory CNS lesions.
Methods
Adoptive-transfer EAE
All experiments were approved by the local animal wel-
fare committee and conformed to the European Com-
munities Council Directive (86/609/EEC). For adoptive
transfer EAE, female naïve SJL/J mice were immunized
with an emulsion containing 250 μg PLP (murine pro-
teolipid peptide p139-151; purity >95%, Pepceuticals,
Leicester, UK) in equal volumes of phosphate buffered
saline (PBS) and Complete Freunds Adjuvant (CFA,
Difco Laboratories, Detroit, MI, USA) and 4 mg/ml
Mycobacterium tuberculosis H37Ra (Difco Laboratories,
Detroit, MI, USA) [14]. Ten days after immunization
cells were extracted from draining lymph nodes and res-
timulated with 12.5 μgP L P / m li nc e l lc u l t u r em e d i u m
(RPMI 1640 supplemented with 2 mM L-glutamine, 100
U/ml penicillin, 100 μg/ml streptomycin and 10% fetal
calf serum) for 4 days at 37°C. Then 8-12 × 10
6 T-cell
blasts in 100 μl PBS were injected intraperitoneally into
syngenic recipients [15].
Mice were daily weighed and scored for neurological
deficits as previously described [16]: 0, unaffected; 1, tail
weakness or impaired righting on attempt to roll over;
2, paraparesis; 3, paraplegia; 4, paraplegia with forelimb
weakness or complete paralysis; score >4, to be sacri-
ficed. Mice with a score of 4 received an intraperitoneal
injection of 200 μl glucose 5% daily.
MRI analysis
After induction of EAE, mice underwent cerebral MRI
between day 5 and 16 post T cell transfer on a 7 Tesla
rodent scanner (Pharmascan 70/16AS, Bruker BioSpin,
Ettlingen, Germany), applying a 20 mm RF-Quadrature-
Volume head coil. Animals received anesthesia via
facemask with 1.5 - 2.0% isoflurane (Forene, Abbot, Wies-
baden, Germany) delivered in 100% O2 under constant
ventilation and body temperature control (Bio Trig Sys-
tem, Bruker BioSpin, Ettlingen, Germany).
We acquired axial and coronal T1-weighted images
(MSME; TE 10.5 ms, TR 322 ms, 0.5 mm slice thickness,
matrix 256 × 256, field of view (FOV) 2.8 cm) before and
after intravenous (i.v.) injection of 0.2 mmol/kg body-
weight Gd-DTPA (gadopentetate dimeglumine, Magne-
vist, Bayer-Schering AG, Berlin, Germany), or 0.1 mmol/
kg bodyweight Gf (Gadofluorine M, kindly provided by
Drs. M. Reinhardt and B. Misselwitz, Bayer-Schering AG,
Berlin, Germany). Gd-DTPA is the current gold standard
for the detection of BBB breakdown in the CNS, showing
as hyperintensity on T1-weighted images instantly after
i.v. application. With a blood half-life of 20 min it is lar-
gely excreted from the organism after 3 h [17]. Gf is a
modified amphiphilic gadolinium complex with a mole-
cular weight of about 1.53 g/mol, also generating bright
enhancement on T1-weighted images. Gf was designed
by adding a perfluoroctyl chain to a gadolinium contain-
ing macrocycle. Gf interacts with hydrophobic proteins
of the extracellular matrix such as collagen, proteogly-
cans, decorin and tenascin, and it is largely bound to
serum albumin after i.v. administration [18]. It has a
plasma half-life of 15.6 h [19]. The dose applied in this
study was approved by previous MRI studies [8,9]; it is
far below the estimated lethal dose of 5 mmol/kg [11].
We investigated a total number of 28 mice by MRI,
comprising 21 EAE and 7 control mice. Fifteen EAE
mice initially received Gd-DTPA. If BBB breakdown
could be detected, Gf was applied and MRI repeated
after 24 h, as established previously [8]. A subgroup of 4
EAE mice was additionally imaged to assess early
kinetics 1 h and 6 h after Gf injection. Two mice were
followed up until complete clinical remission in order to
investigate longitudinal Gf signal decay. A further group
of 6 EAE mice received Gf pre-labelled with the red
fluorescent marker Cy3.5 (Gf-Cy3.5) for subsequent
immunofluorescence histology. Seven naïve mice served
as healthy controls. The kinetic of disease was exclu-
sively studied in vivo owing to ethical concerns, which
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gated. Histological analyses were performed after the
final MR acquisitions.
Histology
Mice were perfused for post mortem analysis in the acute
disease phase within 2 to 5 days after onset. Following the
final MRI, brain and spinal cord were prepared for histol-
ogy, as previously described [8]. Every second slice was
stained with hematoxylin and eosin (H&E) to assess
inflammation. For the evaluation of Gf distribution, conse-
cutive slices were stained with Hoechst 33258 nuclear
stain (1:10000, Molecular Probes, Leiden, the Netherlands)
to visualize cellular organization. We performed immuno-
histochemical staining against IBA-1 to identify macro-
phages/microglia, using the primary antibody rabbit
anti-IBA-1 (1:1000, Wako Chemicals, Neuss, Germany)
a n dg o a ta n t i - r a b b i tC y 2( A m e r s h a m ,M u e n c h e n ,G e r -
many) as secondary antibody [8]. Selected sections were
examined by epifluorescence microscopy and digitally
photographed (Olympus BX-51, Hamburg, Germany).
Data analysis
MRI data were coregistered and corrected for magnetic
field inhomogeneity using MIPAV 6.1 (Center for Infor-
mation Technology, National Institutes of Health,
Bethesda, MD, USA). Statistical analysis was performed
with GraphPad Prism 4.0c (GraphPad Software, Inc.,
S a nD i e g o ,C A ,U S A ) .W ed e t e r m i n e dt h eT 1l e s i o n
load of each individual EAE animal by calculating the
volume of cranial Gf enhancement in T1-weighted
sequences, applying a semi-automated procedure
described previously [20]. In contrast to Gf, enhance-
ment after Gd-DTPA administration was diffuse without
clearly obtainable borders and furthermore, was often
masked by strong intraventricular Gd-DTPA signal due
to Gd-DTPA leakage into the CSF. Accordingly, we
were not able to reliably quantify the volume of Gd-
DTPA-enhancing lesions. The Gf lesion volume was
correlated to 1) the EAE score at the day of imaging
and 2) the day of clinical EAE onset after immunization,
applying Spearman’s nonparametric analysis.
For the assessment of Gf enhancement in CVO,
regions of interest (ROI) were placed in corresponding
positions in all animals, and the mean ROI signal inten-
sity as well as the standard deviation was calculated. We
evaluated the subfornicular organ (SFO), the organum
vasculosum of the lamina terminalis (OVLT), the med-
ian eminence (ME) and the area postrema (AP) in coro-
nal slices. The most reliable ROI placement of the
choroid plexus could be achieved in axial slices of the
lateral ventricles. Choroid plexus examination was gen-
erally more rater demanding due to its widespread
expansion inside the ventricles with high interindividual
anatomic shape differences, and was more prone to
partial volume contaminations compared to other areas.
The mean signal intensitiy of each ROI was expressed
as Gf mean intensity ratio by division with the mean
signal intensity of a masseter muscle ROI for unbiased
and stable comparison between individuals.
Two-tailed Mann-Whitney-U tests were applied to
express differences of the Gf mean intensity ratio in
CVO between naïve versus EAE animals. Correlation
analyses were performed between the Gf mean intensity
ratio and 1) the EAE score at the day of MRI and 2) the
day of clinical disease onset using Spearman’sn o n p a r a -
metric analysis. A receiver-operating characteristic
(ROC) was used to analyze the validity of the Gf mean
intensity ratio in CVO as diagnostic test to distinguish
between EAE mice and controls.
Results
Clinical EAE course and contrast-enhancing lesions (CEL)
Transfer of PLP-specific T cells into recipient animals
resulted in the development of clinical signs in 18 out of
21 mice within 6-13 (mean 9.6) days after immunization.
However, contrast-enhancing lesions (CEL) were detect-
able in all 21 mice in T1-weighted images after Gd-DTPA
and Gf application. Animalsp r o g r e s s e dt oap e a kE A E
score of 2.6 (1-4) within 2 days after onset, and developed
an average Gf-enhanced T1-hyperintense lesion volume of
8.31 mm
3 (table 1). The Gf lesion volume correlated sig-
nificantly with the EAE score at imaging, but not with the
day of clinical EAE onset after immunization (table 2).
Inflammatory plaques were widely distributed
throughout the brain, with predominance to the brain-
stem and the periventricular region. In 15 mice receiv-
ing both, Gd-DTPA and Gf, a total number of 61 CEL
was detected. Among these, 26 were exclusively visible
after Gf administration, but not on Gd-DTPA-enhanced
MRI. The visualization of optic nerve inflammation was
particularly facilitated by Gf application (table 3). Gf-
enhancing plaques appeared concise with well-
delineated borders in comparison to more diffusely
Gd-DTPA-enhancing lesions (figure 1).
Gf tissue enhancement evolved with time delay com-
pared to Gd-DTPA, which indicated BBB breakdown
instantly after application. After 1 h, Gf CEL were
detectable with circumscribed subtle parenchymal signal
enhancement, and developed further within 24 h (figure
2A, arrowheads). T1-hyperintensity maximum was
reached 24 h after application, followed by a gradual sig-
nal drop until complete remission to baseline values
after 14 days (figure 2B).
Visualization of CVO alterations by Gf-enhanced MRI
In addition to inflammatory plaques, Gf revealed altera-
tions in CVO during acute CNS inflammation. Unlike
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bright enhancement of the choroid plexus was evident
already 1 h after Gf injection. Applying Gd-DTPA, the
evaluation of the choroid plexus was not reliably feasi-
ble, since it was frequently obscured by leakage of Gd-
DTPA into the CSF (figure 3).
Gf enhancement of the choroid plexus was a promi-
nent finding in all 21 EAE mice investigated (figure 4,
arrow). Gf accumulation was also observed in other
CVO including the OVLT (figure 4, ellipse), the SFO
(figure 4, square), the ME (figure 4, arrowhead) and the
AP (figure 4, circle). Since CVO may represent major
entry sites for immune cells into the CNS also under
physiological conditions [6,21,22], we were interested to
see whether Gf could visualize CVO “gates” in naïve
animals, too. In all 7 healthy control mice, subtle Gf
enhancement in CVO was detectable (figure 4, 3
rd col-
umn), although considerably less pronounced compared
to EAE mice. We did not assess Gf enhancement in
healthy mice longitudinally.
For a quantitative analysis of differences between EAE
animals and naïve mice, we calculated the mean signal
intensity ratio 24 h after Gf application in the CVO
within these two groups (figure 5). The Gf mean inten-
sity ratio was significantly higher in EAE mice compared
to controls in the choroid plexus (p = 0.008), the SFO
(p = 0.020) and the AP (p = 0.016). No difference was
detected for OVLT and ME.
Gf enhancement in CVO correlates with disease severity
Within EAE animals, Gf mean intensity ratios of SFO
and AP correlated closely with the EAE score at the day
of the MRI investigation; mice with higher disease sever-
ity showed significantly brighter Gf enhancement (table
2 and figure 6A and 6B). Additionally, the Gf mean
intensity ratio of the SFO correlated inversely with the
time span until onset of clinical disease after T cell
transfer; accordingly, Gf enhancement of SFO was sig-
nificantly brighter in EAE mice with early disease onset
(table 2 and figure 6C). The quantitative analysis of the
choroid plexus was technically more demanding com-
pared to CVO regions surrounded by brain parenchyma
such as SFO and AP, due to its expansion throughout
the ventricles with high interindividual anatomical shape
differences. Correlations between clinical EAE features
and choroid plexus enhancement failed to reach statisti-
cal significance, potentially due to partial volume con-
taminations of CSF when conducting a standardized
ROI based semi-automated quantitative analysis.
Gf enhancement of CVO differentiates EAE from control
animals
We were further interested whether the quantitative
assessment of Gf enhancement in different CVO could
serve as diagnostic tool to distinguish between EAE and
Table 1 Clinical EAE course and Gf lesion load
Mouse EAE score at Gf
imaging
Gf lesion load in
mm
3
Day of clinical
onset
1 1 30.5933 10
2 3 22.0243 9
3 3 19.7933 11
4 1 17.3736 13
5 4 13.7473 6
6 2 12.2391 7
7 1 10.4559 9
8 2 9.6347 9
9 1 7.4567 9
10 2 6.3080 9
11 2 6.0699 9
12 2 4.8076 11
13 1 3.2377 11
14 1 3.0483 11
15 1 1.8621 11
16 0 1.4209 11
17 0 1.3857 -
18 3 0.9528 8
19 1 0.8987 9
20 0 0.7135 -
21 0 0.5301 -
mean
(SD)
1.48 (+/-1.12) 8.31 (+/-8.34) 9.61 (+/-1.69)
After detection of cranial blood-brain barrier breakdown by Gd-DTPA, 0.1
mmol/kg bodyweight Gf was applied, and MRI repeated after 24 h. The EAE
score at the day of Gf imaging and the corresponding lesion volume in T1-
weighted Gf-enhanced images are presented. The day of clinical onset is
given as days after T cell transfer.
Table 2 Gf enhancement correlates with clinical EAE parameters
EAE score at Gf imaging Day of clinical onset
Gf lesion volume SFO AP Gf lesion volume SFO AP
Spearman r 0.56 0.66 0.53 -0.09 -0.45 -0.35
95% CI 0.15 to 0.80 0.30 to 0.85 0.08 to 0.79 -0.54 to 0.41 -0.74 to -0.01 -0.70 to 0.14
P value 0.009 0.001 0.021 0.732 0.043 0.147
Significance ** ** * no * no
Correlation of clinical EAE parameters to total Gf lesion volume in T1-weighted images and Gf enhancement (mean intensity ratio) in the subfornicular organ
(SFO) and the area postrema (AP). Correlations for other circumventricular organs were not statistically significant.
*: P value < 0.05; **: P value < 0.01; CI: confidence interval.
Wuerfel et al. Journal of Neuroinflammation 2010, 7:70
http://www.jneuroinflammation.com/content/7/1/70
Page 4 of 11healthy mice. ROC curves were calculated separately for
the Gf mean intensity ratio of the choroid plexus, the
S F Oa n dt h eA P .T h ea r e au n d e rt h eR O Cc u r v ew a s
highly significant for the choroid plexus (p = 0.007) as
well as for the SFO (p = 0.018) and the AP (p = 0.014).
The Gf mean intensity ratio of the choroid plexus was
the best discriminator to identify EAE animals with a
sensitivity of 89% and a specificity of 80% using a cut-
off value of 0.9826 (table 4).
Gf accumulates in the extracellular matrix and is
incorporated by monocytic cells
In order to investigate cellular or molecular mechanisms
of Gf tissue accumulation, we used carbocyanine dye
(Cy3.5) prelabeled contrast agent. MR images were
acquired 24 h and 72 h post application. Directly after
MR measurements, mice were sacrificed and analyzed
histologically. Twentyfour hours post injection, Gf-Cy3.5
produced a strong signal in immune fluorescence micro-
scopy, matching the sites of contrast enhancement in
MRI (figure 7A and 7B). Fluorescence was most intense
within the center of the lesion and vanished towards the
periphery (figure 7A3 and 7B3). Gf appeared to enrich
homogeneously in the extracellular matrix in foci with
high immune cell infiltration (figure 7B4). In corre-
sponding H&E staining, these areas were identified as
inflammatory perivascular cuffs typically seen in EAE
(figure 7A2). Lesion sites were often found in vicinity to
CVO. Please note the high number of periventricular
lesions (table 1) in the proximity to the choroid plexus.
Occasionally, the cell formation suggested migration of
immune cells from CVO to inflammatory cuffs (figure
7A2). Gf enrichment was also detected in inflammatory
sites located at the meninges (figure 7B). However, this
was always associated with a focal inflammatory lesion;
we did not detect a generalized meningeal Gf enhance-
ment. Although the MR signal did not change signifi-
cantly within the first 72 h, microscopically Gf formed
scattered spots of bright red fluorescence neighbouring
Table 3 Contrast-enhancing lesions (CEL) exclusively
detected by Gf
Brain region Total
number
of CEL
Number of
CEL detected
with Gd-
DTPA and Gf
Number of
CEL
detected
exclusively
with Gf
Percentage
of CEL
detected
exclusively
with Gf
Brain stem 14 10 4 28.6
Periventricular 11 9 2 18.2
Optic nerve 10 1 9 90
Trigeminal
nerve
10 6 4 40
Cerebellum 9 6 3 33.3
Vestibular
nerve
52 3 6 0
Cortex 2 1 1 50
61 35 26 42.6
Distribution and number of contrast-enhancing lesions (CEL) after Gd-DTPA
and Gf administration in 15 mice investigated with both contrast agents.
Figure 1 Gf facilitates the detection of inflammatory plaques.
Coronal (A, B, D, E) and axial (C) T1- weighted images are depicted
24 h after Gf injection (left column) and immediately after Gd-DTPA
injection (right column). Periventricular pathology was better
assessable applying Gf (A and B: ovoid). The disruption of the
blood-CSF barrier frequently caused leakage of contrast agent into
the CSF (A, B, E: arrowhead), initially obscuring periventricular
lesions. A parenchymal midbrain lesion is shown exemplary (C:
encircled) that was not seen with Gd-DTPA. Visualization of optic
neuritis (D and E: square) was markedly improved by Gf, since
neighboring intravascular signal prohibited the unambiguous
determination on Gd-DTPA-enhanced images (D and E: arrow).
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likely due to the accumulation in cytosolic vesicles.
Counterstaining with IBA-1 revealed an incorporation of
Gf-C3.5 by macrophages/microglia, predominantly in
regions with prominent cellular infiltrates detected by
H&E staining. A particularly high density of IBA-1 posi-
tive cells with intracellular Gf-C3.5 deposits was
detected in the choroid plexus (figure 7C).
Discussion
This study provides the first in vivo evidence for the
participation of the choroid plexus and other CVO in
neuroinflammation. Applying the novel MRI contrast
agent Gf in high field MRI, we successfully visualized
alterations in the CVO, which in part, correlated to the
severity of CNS inflammation. Transmigration across
the choroid plexus is a well defined entry route for leu-
cocytes into the CNS [1]. Already under physiological
conditions, immune cells home to the choroid plexus
and other CVO [23]. Macrophages and dendritic cells,
key players in CNS antigen presentation, have been
localized to the choroid plexus of naïve mice [6,24].
Recent histopathological studies stressed the role of the
CVO also during inflammation, suggesting an initial
Figure 2 Time course of Gf enhancement. A: Inflammatory plaques located periventricularly (upper row), close to the parahippocampal fissure
(middle row), and within the cerebellum (lower row) are depicted to exemplify the minor signal enhancement 1 h post Gf application compared
to the vast parenchymal enrichment 24 h after Gf injection. B: Gradual Gf signal decline over a time period of 14 days is demonstrated in a
periventricular lesion.
Figure 3 Early Gf enhancement of the choroid plexus. Coronal
T1-weighted images are depicted 1 h after Gf injection (left
column) and immediately after Gd-DTPA injection (right column).
Applying Gf, distinct enhancement of the choroid plexus (arrow
heads) and other CVO was evident early after intravenous injection
and allowed for a reliable quantitative signal analysis. In contrast,
after injection of Gd-DTPA, the disruption of the blood-CSF barrier
frequently caused leakage of contrast agent into the CSF (arrows)
obscuring the choroid plexus and periventricular lesions.
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plexus in EAE: Antigen presentation and subsequent
reactivation of T lymphocytes is facilitated due to the
presence of macrophages and microglia [25] and the
upregulation of major histocompatibility complex anti-
gens in these areas [7,26]. Expression of ICAM-1 and
VCAM-1, molecules that are crucial for lymphocyte
adhesion and transmigration, were induced on choroid
plexus epithelium [6] and other CVO during inflamma-
tion [7].
Although MRI has emerged as a powerful tool to
assess disease activity in MS and EAE, alterations of
CVO during inflammation have not been monitored
in vivo up to date. Nevertheless, the invasion of macro-
phages into inflammatory plaques was demonstrated
in vivo in a recent study on MS patients. This finding
was partially independent from simultaneous BBB
breakdown, and the route of entry is still not completely
understood [27]. We hypothesized that Gf-enhanced
MRI might help to elucidate kinetics of CNS immune
surveillance. Gf was originally developed as a marker for
detecting lymph node metastasis in MR lymphography
[11]. Meding et al. demonstrated, that Gf binds to
serum albumin and components of the extracellular
Figure 4 Gf enhancement in circumventricular organs (CVO). Gf distinctly enhanced the choroid plexus and other CVO in naïve control mice
and more pronounced after induction of EAE: T1-weighted images of the CVO are shown in axial (row 1) and coronal (row 2-4) orientation.
Images were acquired prior to administration of contrast agent (column 1), and 24 h after Gf application in EAE (column 2) and naïve control
mice (column 3). Enhancement of the choroid plexus (arrows), the subfornicular organ (square), the organum vasculosum of the lamina
terminalis (ovoid), the median eminence (arrowhead) and the area postrema (circle) are clearly marked in the EAE mice (column 2). In naïve
mice, only subtle CVO enhancement was detectable (column 3, pins).
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tenascin [18], explaining a possible mechanism of Gf
accumulation in atherosclerotic plaques [12,28]. Further-
more, Gf is taken up by macrophages in vivo and
in vitro [13,29] and thus could highlight spots of
immune activity in autoimmune neuritis, EAE and per-
ipheral nerve degeneration [8,9,13,30]. Recently, Gf was
also applied to detect disease progression in an animal
model of muscular dystrophy [31].
Here we demonstrate, that Gf accumulates weakly in
the choroid plexus and other CVO involved in gating
immune cell migration into the CNS in naïve mice, indi-
cating an immunological function of those organs under
physiological conditions. Interestingly, after initialization
of EAE, pronounced Gf enhancement of the choroid
plexus, the SFO and the AP became visible. Whereas
leakage of Gd-DTPA into the CSF often prevented a
reliable evaluation of the choroid plexus or periventricu-
lar brain regions in EAE mice, Gf-enhanced MRI
allowed for the detailed quantitative evaluation of signal
alterations in these areas. A correlation analysis in EAE
mice exposed that high Gf enhancement of the SFO and
the AP went along with an early disease onset and
severe clinical affection. Regarding the SFO, these
Figure 5 Quantitative comparison of Gf enhancement in
circumventricular organs (CVO). Gf enhancement was
quantitatively assessed computing the Gf mean intensity ratio of the
CVO in T1-weighted images 24 h after Gf application. The
comparison between EAE and naïve control animals was performed
using two-tailed Mann-Whitney-U tests. Gf enhancement in EAE
mice was significantly higher in the choroid plexus (**: P = 0.008),
the subfornicular organ (*: P = 0.020) and the area postrema (*: P =
0.016). SFO: subfornicular organ; OVLT: organum vasculosum of the
lamina terminalis; ME: median eminence; AP: area postrema.
Figure 6 Gf enhancement correlates with clinical parameters. Correlation analyses were performed according to Spearman. The signal
intensity (Gf mean intensity ratio) of the subfornicular organ (SFO) (A, P = 0.001) and the area postrema (AP) (B, P = 0.021) 24 h post injection
correlated significantly to the corresponding EAE scores at the time of scanning. Additionally, the time needed from T cell transfer to disease
onset correlated inversely with the mean intensity ratio of the SFO (C, P = 0.043) but not the AP (D, P = 0.147). Each dot depicts the data point
of one mouse. For further statistics see table 2.
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same clinical parameters to the Gf lesion volume.
Furthermore, we found that calculating the Gf mean
intensity ratio in CVO can be applied as diagnostic tool
to discriminate EAE from control animals, with a sensi-
tivity of 89% and a specificity of 80% for the choroid
plexus. In histological sections, we could confirm an
accumulation of Gf in the choroid plexus stroma initi-
ally and a subsequent internalization into macrophages/
microglia resident in the choroid plexus after 72 h.
However, we did not detect significant alterations of the
enhancement pattern in OVLT and ME during EAE.
The predominance of the observed changes in periven-
tricular and brain stem CVO might reflect a heightened
regional vulnerability in developing inflammatory pla-
ques during EAE in these areas [8].
Furthermore, we noted a high sensitivity of Gf to
detect BBB leakage and associated parenchymal inflam-
mation, particularly optic neuritis, resulting in a 42%
increased number of contrast-enhancing lesions com-
pared to Gd-DTPA-enhanced MRI, in line with a recent
report by Bendszus et al. [9]. In the circulation, Gf is
largely bound to albumin [18]. Brain parenchymal
enhancement is due to a locally disturbed BBB and sub-
sequent capturing of Gf molecules by protein interaction
[10]. There is no evidence for an active transport
mechanism of Gf across the intact BBB. Gf accumulated
with delay within CNS lesions yielding a signal intensity
peak after 24 h in contrast to Gd-DTPA that immedi-
ately passed the disrupted BBB. Gf enhancement, as
quantified in our study, thus reflects the accumulation
during 24 h of focal BBB disruption. High binding
affinity to plasma albumin and extracellular matrix pro-
teins may explain the delayed initial CNS tissue accu-
mulation but also the persisting presence of Gf within
the brain parenchyma for up to 10 days [9,18]. The
inflammatory cascade in EAE includes a plethora of
effector mechanisms such as secretion of matrix metal-
loproteases and other digesting enzymes by immune
cells [32] initiating tissue degradation. Proteins liberated
during this process are likely to trap Gf once it passed
the disrupted BBB [10]. The histological analysis apply-
ing fluorescent Gf likewise indicated a diffuse extracellu-
lar enrichment pattern. The clearance of Gf from the
brain parenchyma after 14 days might be a result of a
gradual loss of local molecule binding affinity as well as
the general clearance and molecular turnover at lesion
sites. We also noted a local uptake of Gf molecules by
macrophages/microglia. However, we could not establish
a correlation to repair mechanisms such as remyelina-
tion (data not shown).
Despite a delayed brain parenchymal enhancement Gf
accumulated in CVO already 1 h after application. CVO
are primarily exposed to Gf molecules due to the dense
capillary network devoid of a tight BBB. Endothelial
cells of the choroid plexus and other CVO express pro-
teoglycans, fibronectin and other extracellular matrix
proteins [33,34], which may bind Gf. During CNS
inflammation, such molecules are upregulated and med-
iate adhesion and subsequent transmigration of immune
cells into the CNS [33,35]. Thus, adhesion to extracellu-
lar matrix proteins presented on CVO endothelium
might explain both, Gf enhancement in CVO of healthy
control mice and increased enhancement under inflam-
matory conditions.
Conclusions
In summary, in this first in vivo MRI investigation visua-
lizing inflammatory alterations in the CVO, Gf enhance-
ment correlated to disease severity as well as to time of
onset, indicating an active participation of the CVO in
CNS inflammation. Gf enhancement in CVO was a
good discriminator between healthy and EAE animals.
Our results suggest that Gf enhancement could serve as
sensitive marker for different hallmarks of CNS inflam-
mation, including molecular “arming”,i m m u n ec e l l
recruitment, BBB breakdown and tissue damage. How-
ever, extensive preclinical testing is needed before a clin-
ical application of Gf. This is eligible since Gf could not
only facilitate the paraclinical diagnosis and follow-up of
neuroinflammatory diseases such as MS but may also
help to elucidate basic principles of CNS immunity.
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